Navigation Links
Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
Date:5/5/2008

ed their child's pain

as significantly lower than parents of children receiving the sham

placebo device (p<0.001).(1)

Zingo was found to be well tolerated in this patient population, with no serious drug-related adverse events reported. The most common skin assessment findings were redness (erythema), red dots (petechiae) and swelling (edema) at the site of administration. The incidence of adverse events with Zingo was no higher than with sham placebo.(1) Demographic characteristics and sites of administration were evenly distributed across treatment groups.

The U.S. Food and Drug Administration (FDA) approved Zingo last year for children three to 18 years of age based on the results of the COMFORT-003 study and a second large clinical trial, COMFORT-004, which also found that use of Zingo was related to significantly less peripheral venous access procedural pain in children.

About Zingo and Venous Access Procedures

Zingo is a needle-free system that delivers lidocaine powder into the skin and provides analgesia in one to three minutes after administration.

In clinical trials, Zingo was well-tolerated. The most common adverse reactions in clinical trials were erythema, petechiae, and edema at the site of administration.(7) Full prescribing information is available at http://www.anesiva.com/img/ZingoPackage.pdf.

In addition to the hospital population, opportunities exist for Zingo in children in hemodialysis centers, as well as physicians' offices and clinical laboratories. In March, Anesiva submitted a supplemental New Drug Application with the U.S. Food and Drug Administration to expand the indication for Zingo to treat the pain associated with peripheral IV insertions and blood draws in adults.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
2. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
3. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
4. Anesiva Defines Regulatory Pathway for Adlea with FDA
5. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
6. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
7. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
8. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
10. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
11. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research ... "Global and Chinese Medical X-ray Film Industry Report ... http://photos.prnewswire.com/prnh/20130307/600769 Global And Chinese ... and in-depth study on the current state of the ... the Chinese situation. The report provides a basic ...
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2
... presented this week at the International Federation of Clinical ... lower diagnostic threshold for troponin improves clinical outcomes and ...  Troponin is a protein found inside of heart cells ... or reduced blood supply.   Cardiac troponin ...
... 18, 2011 The core technology of ViewRay™, Inc., ... radiotherapy technologies, has been issued landmark patents in the ... device company, holds the exclusive worldwide license for the ... technology was invented by company founder James F. Dempsey, ...
Cached Medicine Technology:Study Shows Improved Patient Management and Outcome Using Abbott's Sensitive Troponin Assay 2Study Shows Improved Patient Management and Outcome Using Abbott's Sensitive Troponin Assay 3Study Shows Improved Patient Management and Outcome Using Abbott's Sensitive Troponin Assay 4Landmark Patents Issued for ViewRay Technology 2
(Date:7/13/2014)... 14, 2014 Worldwide ladies are extremely ... Angeldress.co.uk has taken a different approach and has created ... are offered in more colour choices that responded directly ... brand of women’s special occasion apparels. The company’s pink ... specialists are working hard to create the best products ...
(Date:7/13/2014)... 13, 2014 Carolinas Healthcare System celebrated ... the Carolinas HealthCare System - Anson located in Anson ... Anson Community Hospital in Wadesboro. , Located on U.S. ... from the previous facility. Situated on a 10-acre site, ... an emergency room drop-off, helipad, healing garden, and 15 ...
(Date:7/13/2014)... July 13, 2014 Recently, MillionaireCasket.com, a well-known ... oak caskets . Additionally, the company’s chief executive officer ... the new oak caskets are offered at discounted prices, from ... am concerned, quality caskets are in huge demand in the ... caskets . We have a lot of high quality ...
(Date:7/13/2014)... 13, 2014 Advanced boilers are ... least amount of fossil fuels, produce high-capacity power, ... to increased global warming and climate change concerns, ... reduce harmful gas emissions and pollutants coming from ... in the global advance boilers market., The global ...
(Date:7/13/2014)... Serena Gordon HealthDay ... A new type of sensor for people with diabetes ... using saliva instead of blood, researchers report. Scientists at ... tested it using artificial saliva. It uses light, metal and ... sugar. "Everybody knows that diabetics have to prick their ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Announces Summer Sale For Pink And Red Bridesmaid Dresses; The Current Discount Is Up To 80% Off 2Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3
... N.C. Older adults who take drugs designed to ... incontinence, high blood pressure and allergies are more ... of daily living and to walk slower, according to ... of Medicine and colleagues. , The findings, which involve ...
... find decongestants and antihistamines taken most often , , ... 10 U.S. children uses one or more cough and ... research from Boston University. , While cough and cold ... States, how frequently they are used had not been ...
... 2 The following is,being issued today by ... will launch an unfair labor practice strike against,Inter-Con ... 6. This is the,first-ever group of hospital security ... on workers who were trying to form a,union ...
... Inc.,(Nasdaq: OSTE ) announces today that on April ... response to its notification to Nasdaq that,Robert W. Gunn, ... of,Directors, Audit and Compensation Committees, passed away unexpectedly on,April ... independent directors,serving on its Audit Committee and is not ...
... has already worked against breast, colon cancers , , FRIDAY, ... new targets for treatments that block tumor blood vessel ... metastasis -- have been identified by researchers at the ... use of the drug bevacizumab (Avastin) to target the ...
... 2 American Pacific Corporation,(Nasdaq: APFC ) today ... financial results on Thursday, May 8, 2008. John R. ... in a,teleconference to review the financial results and outlook ... Thursday, May 8, 2008 at 1:30 p.m. PDT.,To access ...
Cached Medicine News:Health News:Commonly used medications associated with impaired physical function in older adults 2Health News:10% of U.S. Kids Using Cough Medicine Every Week 2Health News:First-Ever Group of Hospital Security Officers to Strike over Unfair Labor Practices, Walk out of Facilities Across California on May 6 2Health News:Osteotech Announces the Unexpected Passing of Audit Committee Member Leads to Receipt of Nasdaq Deficiency Letter 2Health News:New Targets Found That Stop Tumor Growth 2Health News:American Pacific to Release Financial Results and Hold Fiscal 2008 Second Quarter Investor Teleconference 2
Zero clearance, front breathing, undercounter refrigeration system....
Designed to meet the requirements of reagent grade water for routine analysis....
... Basic Laboratory Needs, Synergy systems produce ultrapure water ... 1 to 1.2 L/min to meet the basic ... incorporates a dual-wavelength UV lamp (185 nm and ... of organic contaminants (< 5 ppb TOC when ...
... Compact System Produces Type I Water Directly from ... designed for scientists who need 5 to 15 ... not have easy access to acceptable quality pretreated ... 0.6 L/min of ultrapure (Type I) water on ...
Medicine Products: